Precision in Occupational Exposure Limits (OEL)

The rise of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), oncology drugs, and complex biologicals has fundamentally raised the stakes on the manufacturing floor. A miscalculated Occupational Exposure Limit doesn’t just create a compliance gap — it puts real people at risk of chronic toxicity, reproductive harm, and occupational asthma. At the same time, an arbitrarily low OEL forces facilities into unnecessary Category 5 containment, squandering millions in capital expenditure on equipment that the toxicology simply does not justify.

This white paper provides a rigorous, practical guide to OEL derivation in pharmaceutical manufacturing — authored by PLG’s UKRT- and ERT-certified toxicologists who work at the intersection of science, regulation, and facility economics every day.

The precise definitions of OEL and Occupational Exposure Band (OEB), and how the band you assign drives every containment decision in your facility.

The full OEL formula: from NOAEL selection and uncertainty factors (UF1–UF5) to systemic bioavailability correction (α) and modifying factors for compounds with long half-lives.

The route-to-route extrapolation challenge: why converting oral animal data to human inhalation risk is where under-qualified assessors most frequently fail — and the pharmacokinetic rigour required to get it right.

The dermal hazard trap: why ignoring skin notation leaves a critical gap in your PPE protocols.

The regulatory and legal framework: OSHA/NIOSH, COSHH, ECHA/REACH, and the ISPE Containment Manual.

EHS managers, industrial hygienists, and regulatory affairs professionals involved in HPAPI handling, as well as operations and CAPEX decision-makers evaluating containment investments.

The Authors:

	Vishnu Jatoth, Medical Writing Specialist & Toxicologist
	Amit Salvi, Clinical & Non-Clinical Operations Director